Showing results (561-570 of 598) with videos related to

Sort By:
Pageof 60
Gates Open Research|November 23, 2023
Higher mortality associated with the SARS-CoV-2 Delta variant in the Western Cape, South Africa, using RdRp target delay as a proxy: a cross-sectional studyHannah Hussey, Mary-Ann Davies, Alexa Heekes, et al.
Cell Metabolism|October 4, 2016
Defining the Nutritional and Metabolic Context of FGF21 Using the Geometric FrameworkSamantha M Solon-Biet, Victoria C Cogger, Tamara Pulpitel, et al.
European Journal of Heart Failure|September 8, 2022
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trialKelley R H Branch, Gilles R Dagenais, Alvaro Avezum, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 2, 2022
Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections - a survival analysisHannah Hussey, Mary-Ann Davies, Alexa Heekes, et al.
Eclinicalmedicine|March 2, 2026
Minimum combined sleep, physical activity, and nutrition variations associated with lifeSPAN and healthSPAN improvements: a population cohort studyNicholas A Koemel, Raaj K Biswas, Matthew N Ahmadi, et al.
The Lancet. Diabetes & Endocrinology|June 21, 2021
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trialHarpreet S Bajaj, Hertzel C Gerstein, Purnima Rao-Melacini, et al.
European Heart Journal|November 16, 2020
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metforminGiulia Ferrannini, Hertzel Gerstein, Helen Martina Colhoun, et al.
Cardiovascular Diabetology|November 26, 2020
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysisGilles R Dagenais, Lars Rydén, Lawrence A Leiter, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2022
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND TrialTali Cukierman-Yaffe, Hertzel C Gerstein, Jan Basile, et al.
The Lancet. Neurology|June 21, 2020
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialTali Cukierman-Yaffe, Hertzel C Gerstein, Helen M Colhoun, et al.
Pageof 60